-
Product Insights
New![]()
EPR Eye Biomass Power Plant
EPR Eye Biomass Power Plant is a biopower project located in England, United Kingdom. The project is owned by Energy Power Resources Ltd and was developed by Aalborg Energie Technik AS. The project came online in 1992. Empower your strategies with our EPR Eye Biomass Power Plant report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase,...
-
Company Insights
New![]()
Innovation and Patenting activity of Aier Eye Hospital Group Co Ltd Q3 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Aier Eye Hospital Group Co Ltd Q3 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – EYE-103 in Diabetic Macular Edema
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. EYE-103 in Diabetic Macular Edema Drug Details: Monoclonal antibody is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Rebamipide in Keratoconjunctivitis Sicca (Dry Eye)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Rebamipide in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Rebamipide (DWP-DN11) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tavilermide in Keratoconjunctivitis Sicca (Dry Eye)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Tavilermide in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Tavilermide (MIM-D3) was under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Palovarotene in Keratoconjunctivitis Sicca (Dry Eye)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Palovarotene in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Palvarotene (Sohonos) a member of the retinoid...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – A-197 in Keratoconjunctivitis Sicca (Dry Eye)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. A-197 in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: A-197 is under development for treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Betamethasone in Keratoconjunctivitis Sicca (Dry Eye)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Betamethasone in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Betamethasone is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Pilocarpine in Keratoconjunctivitis Sicca (Dry Eye)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pilocarpine in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Pilocarpine is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Reproxalap in Keratoconjunctivitis Sicca (Dry Eye)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Reproxalap in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Reproxalap (ADX-102) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Progesterone in Keratoconjunctivitis Sicca (Dry Eye)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Progesterone in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: GL-101 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Tanfanercept in Keratoconjunctivitis Sicca (Dry Eye)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Tanfanercept in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Tanfanercept (HL-036) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lacripep in Keratoconjunctivitis Sicca (Dry Eye)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lacripep in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: Lacripep is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Acoltremon in Keratoconjunctivitis Sicca (Dry Eye)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Acoltremon in Keratoconjunctivitis Sicca (Dry Eye)Drug Details:Acoltremon (AR-15512) is under development for the treatment of dry...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – INexin in Keratoconjunctivitis Sicca (Dry Eye)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. INexin in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: aCT11 (alphaCT11) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – KJ-16001 in Keratoconjunctivitis Sicca (Dry Eye)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. KJ-16001 in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: KJ-16001 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – RP-101 in Keratoconjunctivitis Sicca (Dry Eye)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. RP-101 in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: RP-101 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – YPP-10 in Keratoconjunctivitis Sicca (Dry Eye)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YPP-10 in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: YP-P10 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – SY-201 in Keratoconjunctivitis Sicca (Dry Eye)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SY-201 in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: SY-201 is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ST-100 in Keratoconjunctivitis Sicca (Dry Eye)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. ST-100 in Keratoconjunctivitis Sicca (Dry Eye) Drug Details: ST-100 is under development for the...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.